3-庚酰基吡啶 | 6294-61-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-庚酰基吡啶
• 英文名称: n-hexyl 3-pyridyl ketone
• 英文别名: 3-heptanoylpyridine；1-[3]pyridyl-heptan-1-one；1-[3]Pyridyl-heptan-1-on；1-pyridin-3-yl-heptan-1-one；1-(Pyridin-3-yl)heptan-1-one；1-pyridin-3-ylheptan-1-one
• CAS: 6294-61-7
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: WJKSBMMOBQQEDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-庚酰基吡啶 在 copper(l) iodide 、 二甲基硫 、 sulfur 作用下， 以 萘烷 为溶剂， 反应 7.17h， 生成 1-(4-hexylpyridin-3-yl)heptan-1-one
  参考文献：
  名称：

  Comins, Daniel L.; Stroud, Eric D., Heterocycles, 1986, vol. 24, # 11, p. 3199 - 3201

  摘要：

  DOI：
• 作为产物：
  描述：

  氯化烟碱盐酸盐 在 吡啶 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 4.75h， 生成 3-庚酰基吡啶
  参考文献：
  名称：

  WO2008/129054

  摘要：

  公开号：

文献信息

• Dual inhibitors of thromboxane A2 synthase and 5-lipoxygenase with scavenging activity of active oxygen species (AOS). Synthesis of a novel series of (3-pyridylmethyl)benzoquinone derivatives
  作者：Shigenori Ohkawa、Shinji Terao、Zenichi Terashita、Yumiko Shibouta、Kohei Nishikawa

  DOI：10.1021/jm00105a042

  日期：1991.1

  A novel series of (3-pyridylmethyl)benzoquinone derivatives was molecular designed and synthesized for the dual purpose of inhibiting thromboxane A2 and leukotriene biosynthesis enzymes and scavenging active oxygen species (AOS). They were evaluated for inhibition of TXA2 synthase, inhibition of 5-lipoxygenase, and for their scavenging activity of AOS using the thiobarbituric acid method. 2,3,5-Tr

  为了抑制血栓烷A2和白三烯生物合成酶并清除活性氧（AOS）的双重目的，设计并合成了一系列新型的（3-吡啶基甲基）苯醌衍生物。使用硫代巴比妥酸法评价了它们对TXA2合酶的抑制，对5-脂氧合酶的抑制以及对AOS的清除活性。2,3,5-三甲基-6-（3-吡啶基甲基）-1,4-苯醌（24，CV-6504）是最有前途的衍生物，因为它显示出有效的AOS清除活性（抑制大鼠脑匀浆中的脂质过氧化作用： IC50 = 1.8 x 10（-6）M）以及对这两种酶的有效，特异性和良好平衡的抑制作用（对人血中TXA2合酶的抑制作用，IC50 = 3.3 x 10（-7）M；抑制作用对人血中的5-脂氧合酶的抑制作用，IC50 = 3.6 x 10（-7）M）。在大鼠模型中由阿霉素诱导的蛋白尿中，每天10 mg / kg（po）的化合物24抑制蛋白尿的作用超过50％。但是，不能通过单用血栓烷A2合酶[（E）-7-苯基-
• Certain benzoquinones, naphthoquinones and derivatives thereof which
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04985447A1

  公开（公告）日：1991-01-15

  Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is hydrogen atom or methyl group; R.sup.4 is nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or carboxyl group which may be esterified or amidated; Z is ##STR2## --CH.dbd.CH--, ##STR3## or ##STR4## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ]), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of poly unsaturated fatty acids, particularly two or more inhibitition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therpeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.

  通式为##STR1##的醌衍生物（其中，R.sup.1和R.sup.2，相同或不同，指氢原子，甲基或甲氧甲基基团，或R.sup.1和R.sup.2结合形成--CH.dbd.CH--CH.dbd.CH--; R.sup.3是氢原子或甲基基团; R.sup.4是可能被取代的含氮杂环基团; R.sup.5是氢原子，甲基基团，可能被取代的羟甲基基团，或可酯化或酰胺化的羧基; Z是##STR2## --CH.dbd.CH--, ##STR3## 或 ##STR4##（其中，R'是氢原子或甲基基团）; n是0到12的整数，m是0到3的整数，k是0到7的整数，但当m为2或3时，Z和k能够在[ ]中所示的重复单位中适当变化），以及其羟醌衍生物，是新颖的化合物，具有改善多不饱和脂肪酸代谢的效果，特别是抑制脂肪酸过氧化物的产生，抑制5-脂氧合酶途径代谢物的产生，抑制血栓素A.sub.2合酶，血栓素A.sub.2受体拮抗作用和活性氧自由基清除作用，并可用作药物，如抗血栓剂，抗血管收缩剂，抗哮喘剂，抗过敏剂，治疗银屑病的药物，改善心脏，脑和心血管系统的药物，治疗肾炎的药物，活性氧清除剂，抗癌剂，改善花生四烯酸级联产物控制的药物等。
• Certain benzoquinones, naphthoquinones, corresponding hydroquinones
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04851413A1

  公开（公告）日：1989-07-25

  Quinone derivatives represented by the general formula ##STR1## (wherein, R.sup.1 and R.sup.2, the same or different, refer to a hydrogen atom, methyl or methoxymethyl group, or R.sup.1 and R.sup.2 bind together to form --CH.dbd.CH--CH.dbd.CH--; R.sup.3 is a hydrogen atom or methyl group; R.sup.4 is a nitrogen-containing heterocyclic group which may be substituted; R.sup.5 is a hydrogen atom, methyl group, hydroxymethyl group which may be substituted, or a carboxyl group which may be esterified or amidated; Z is ##STR2## (wherein, R' is hydrogen atom or methyl group); n is an integer from 0 through 12, m is an integer from 0 through 3, and k is an integer from 0 through 7, providing that, when m is 2 or 3, Z and k are able to vary appropriately in the repeating unit shown in [ ]), and the hydroquinone derivatives thereof, are novel compounds, possess improvement effects of metabolism of polyunsaturated fatty acids, particularly two or more of inhibition of production of fatty acid peroxides, inhibition of production of metabolites in 5-lipoxygenase pathway, inhibition of thromboxane A.sub.2 synthetase, thromboxane A.sub.2 receptor antagonism and scavenging action of active oxygen species, and of use as drugs, such as antithrombotics, anti-vascular constriction agents, anti-asthma agent, antiallergic agents, therapeutics for psoriasis, agents for improvement in heart, brain and cardiovascular systems, therapeutics for nephritis, active oxygen-eliminating agents, anticancer agents, agents for improvement of control of arachidonate cascade products, etc.

  通式 ##STR1## 所代表的醌衍生物（其中，R.sup.1和R.sup.2，相同或不同，指氢原子，甲基或甲氧甲基基团，或R.sup.1和R.sup.2结合在一起形成--CH.dbd.CH--CH.dbd.CH--; R.sup.3是氢原子或甲基基团；R.sup.4是含氮杂环基团，可以被取代；R.sup.5是氢原子，甲基基团，可以被取代的羟甲基基团，或可以酯化或酰化的羧基；Z是##STR2## （其中，R'是氢原子或甲基基团）；n是0到12的整数，m是0到3的整数，k是0到7的整数，但当m为2或3时，Z和k能够适当地在[ ]所示的重复单元中变化），以及其羟醌衍生物，是新化合物，具有改善多不饱和脂肪酸代谢的效果，特别是抑制脂肪酸过氧化物的产生，抑制5-脂氧合酶代谢物的产生，抑制血栓素A.sub.2合成酶，血栓素A.sub.2受体拮抗作用和活性氧自由基的清除作用，可以用作药物，例如抗血栓剂，抗血管收缩剂，抗哮喘剂，抗过敏剂，治疗银屑病的药物，改善心脏，脑和心血管系统的药物，治疗肾炎的药物，清除活性氧的药物，抗癌药物，改善花生四烯酸级联产物控制的药物等。
• Heterocyclic Compounds with Affinity to Muscarinic Receptors
  申请人：Stoit Axel

  公开号：US20090018160A1

  公开（公告）日：2009-01-15

  The present invention relates to heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof wherein the heterocycle comprises two double bonds which may be present at several positions, and which are represented by the dashed lines (---); the heterocycle contains two heteroatoms, W is N or NH; Y is CH, O or NH, wherein if Y is O, X 1 is CH and X 2 is C-Z-R2 or C—R3, wherein Z is NH, O, or S; and if Y is CH or NH, one of X 1 and X 2 is CH or N, wherein if X 1 is CH or N, X 2 is C-Z-R2 or C—R3, and if X 2 is CH or N, X 1 is C-Z-R2 or C—R3, wherein Z is NH or S; R1 is chosen from structures (a), (b) and (c): R2 is chosen from (C 1 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, oxo, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle (optionally substituted with halogen), phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and R3 is chosen from (C 4 -C 10 )alkyl, (C 2 -C 10 )alkenyl and (C 2 -C 10 )alkynyl, optionally independently substituted with one or more substituents chosen from halogen, hydroxy, cyano, (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkenyloxy, (C 1 -C 6 )alkenylthio, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 5 -C 7 )cycloalkyl, a 5-membered unsaturated heterocycle optionally substituted with halogen, phenyl, phenyloxy and phenylthio, wherein the phenyl group is optionally substituted with halogen; and optionally, when R2 is an unbranched (C 2 -C 8 )alkyl, R2 links to formula (Ia) or a pharmaceutically acceptable salt, a solvate or hydrate thereof, through the X 1 a or X 2 a of formula (Ia), wherein if X 1 is CH or N, X 1 a is CH or N and X 2 a is C-Za-, or if X 1 is C-Z-R2, X 1 a is C-Za- and X 2 a is CH or N, wherein X 1 a or X 2 a having Za links to R2; and the symbols Wa, Ya and Za and the substituent R1 a have the same meanings as defined previously for the symbols W, Y and Z and the substituent R1, and are not independently selected, each of the symbols Wa, Ya and Za and the substituent R1 a representing identical symbols and substituents, respectively, as the symbols W, Y and Z and the substituent R1 in the other part of the structure of formula (I). The compounds of the invention have affinity to muscarinic receptors and may be used in the treatment, alleviation or prevention of muscarinic receptor mediated diseases and conditions.

  本发明涉及公式（I）的杂环化合物或其药学上可接受的盐、溶剂或水合物，其中杂环包含两个双键，可以存在于多个位置，并由虚线（---）表示；杂环含有两个杂原子，W为N或NH；Y为CH，O或NH，其中如果Y为O，X1为CH，X2为C-Z-R2或C—R3，其中Z为NH，O或S；如果Y为CH或NH，X1和X2中的一个为CH或N，其中如果X1为CH或N，X2为C-Z-R2或C—R3，如果X2为CH或N，则X1为C-Z-R2或C—R3，其中Z为NH或S；R1选择自结构（a）、（b）和（c）：R2选择自（C1-C10）烷基，（C2-C10）烯基和（C2-C10）炔基，可选地独立取代一个或多个取代基，所选的取代基选择自卤素，羟基，氰基，氧代基，（C1-C6）烷氧基，（C1-C6）烷基硫基，（C1-C6）烯基氧基，（C1-C6）烯基硫基，（C1-C4）烷氧基（C1-C4）烷氧基，（C5-C7）环烷基，一种5-成员不饱和杂环（可选地取代卤素），苯基，苯氧基和苯硫基，其中苯基可选地取代卤素；R3选择自（C4-C10）烷基，（C2-C10）烯基和（C2-C10）炔基，可选地独立取代一个或多个取代基，所选的取代基选择自卤素，羟基，氰基，（C1-C6）烷氧基，（C1-C6）烷基硫基，（C1-C6）烯基氧基，（C1-C6）烯基硫基，（C1-C4）烷氧基（C1-C4）烷氧基，（C5-C7）环烷基，一种5-成员不饱和杂环，可选地取代卤素，苯基，苯氧基和苯硫基，其中苯基可选地取代卤素；可选地，当R2为直链（C2-C8）烷基时，R2通过公式（Ia）或其药学上可接受的盐、溶剂或水合物与公式（I）连接，其中如果X1为CH或N，X1a为CH或N，X2a为C-Za-，或如果X1为C-Z-R2，X1a为C-Za-，X2a为CH或N，其中X1a或X2a具有Za连接到R2；符号Wa，Ya和Za和取代基R1a具有与先前定义的符号W，Y和Z和取代基R1相同的含义，并且不能独立选择，每个符号Wa，Ya和Za和取代基R1分别表示与公式（I）结构的其他部分中的符号W，Y和Z和取代基R1相同的符号和取代基。本发明的化合物具有亲和力，可以用于治疗、缓解或预防毒蕈碱受体介导的疾病和症状。
• Heterocyclic compounds with affinity to muscarinic receptors
  申请人：Solvay Pharmaceuticals B.V.

  公开号：US08084473B2

  公开（公告）日：2011-12-27

  The present invention relates to heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof.

  本发明涉及公式(I)的杂环化合物，或其药学上可接受的盐、溶剂化合物或水合物。